203 related articles for article (PubMed ID: 29504510)
1. HCV genotype-3h, a difficult-to-diagnose sub-genotype in the DAA era.
Minichini C; Starace M; De Pascalis S; Macera M; Occhiello L; Caroprese M; Vitrone M; Iovinella V; Guerrera B; Masarone M; Coppola N
Antivir Ther; 2018; 23(7):605-609. PubMed ID: 29504510
[TBL] [Abstract][Full Text] [Related]
2. High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world.
Pérez AB; Chueca N; García-Deltoro M; Martínez-Sapiña AM; Lara-Pérez MM; García-Bujalance S; Aldámiz-Echevarría T; Vera-Méndez FJ; Pineda JA; Casado M; Pascasio JM; Salmerón J; Alados-Arboledas JC; Poyato A; Téllez F; Rivero-Juárez A; Merino D; Vivancos-Gallego MJ; Rosales-Zábal JM; García F;
J Hepatol; 2019 Nov; 71(5):876-888. PubMed ID: 31279901
[TBL] [Abstract][Full Text] [Related]
3. Profile of paritaprevir/ritonavir/ombitasvir plus dasabuvir in the treatment of chronic hepatitis C virus genotype 1 infection.
Smith MA; Lim A
Drug Des Devel Ther; 2015; 9():6083-94. PubMed ID: 26622169
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of retreatment with ombitasvir/paritaprevir/ritonavir and dasabuvir+sofosbuvir+ribavirin in patients with chronic hepatitis C, subtype 1b, and cirrhosis, who failed previous treatment with first- and second-generation NS5A inhibitors.
Fedorchenko SV; Martynovych T; Klimenko Z; Solianyk I
J Med Virol; 2021 Aug; 93(8):4975-4981. PubMed ID: 33704798
[TBL] [Abstract][Full Text] [Related]
5. HCV Resistance Profile Evolution in a GT1b, DAA-Naive Patient Before, On, and After Failing Triple DAA Therapy.
Knops E; Schübel N; Heger E; Neumann-Fraune M; Kaiser R; Inden S; Kalaghatgi P; Sierra S
Clin Gastroenterol Hepatol; 2017 Feb; 15(2):307-309. PubMed ID: 27670383
[No Abstract] [Full Text] [Related]
6. Interferon-Free Regimen: Equally Effective in Treatment Naive and Experienced HCV Patients.
Fofiu C; Boeriu A; Coman F; Fofiu A; Panic N; Bulajic M; Dobru D
Ann Hepatol; 2019; 18(1):137-143. PubMed ID: 31113582
[TBL] [Abstract][Full Text] [Related]
7. Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir: A Review in Chronic HCV Genotype 1 Infection.
Deeks ED
Drugs; 2015 Jun; 75(9):1027-38. PubMed ID: 26059288
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with ribavirin for the treatment of HCV genotype 1b compensated cirrhosis in patients aged 70 years or older.
Trifan A; Stanciu C; Gheorghe L; Iacob S; Curescu M; Cijevschi Prelipcean C; Stefanescu G; Girleanu I; Chiriac S; Mihai C; Brisc C; Goldis A; Sporea I; Miftode E; Bataga S; Rogoveanu I; Preda C; Caruntu FA; Singeap AM
Medicine (Baltimore); 2017 Dec; 96(50):e9271. PubMed ID: 29390377
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with low-dose ribavirin in patients with chronic hepatitis C virus genotype 1a infection without cirrhosis.
Poordad F; Sedghi S; Pockros PJ; Ravendhran N; Reindollar R; Lucey MR; Epstein M; Bank L; Bernstein D; Trinh R; Krishnan P; Polepally AR; Unnebrink K; Martinez M; Nelson DR
J Viral Hepat; 2019 Aug; 26(8):1027-1030. PubMed ID: 30980576
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis.
Lawitz E; Makara M; Akarca US; Thuluvath PJ; Preotescu LL; Varunok P; Morillas RM; Hall C; Mobashery N; Redman R; Pilot-Matias T; Vilchez RA; Hézode C
Gastroenterology; 2015 Oct; 149(4):971-80.e1. PubMed ID: 26170136
[TBL] [Abstract][Full Text] [Related]
11. Ombitasvir/paritaprevir/ritonavir and dasabuvir tablets for hepatitis C virus genotype 1 infection.
Klibanov OM; Gale SE; Santevecchi B
Ann Pharmacother; 2015 May; 49(5):566-81. PubMed ID: 25680759
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb-V and dialysis in Spanish clinical practice - Vie-KinD study.
Londoño MC; Riveiro-Barciela M; Ahumada A; Muñoz-Gómez R; Roget M; Devesa-Medina MJ; Serra MÁ; Navascués CA; Baliellas C; Aldamiz-Echevarría T; Gutiérrez ML; Polo-Lorduy B; Carmona I; Benlloch S; Bonet L; García-Samaniego J; Jiménez-Pérez M; Morán-Sánchez S; Castro Á; Delgado M; Gea-Rodríguez F; Martín-Granizo I; Montes ML; Morano L; Castaño MA; de Los Santos I; Laguno M; Losa JE; Montero-Alonso M; Rivero A; de Álvaro C; Manzanares A; Mallolas J; Barril G; González-Parra E; García-Buey L
PLoS One; 2019; 14(9):e0221567. PubMed ID: 31550267
[TBL] [Abstract][Full Text] [Related]
13. Evolutionary Pathways to Persistence of Highly Fit and Resistant Hepatitis C Virus Protease Inhibitor Escape Variants.
Jensen SB; Fahnøe U; Pham LV; Serre SBN; Tang Q; Ghanem L; Pedersen MS; Ramirez S; Humes D; Pihl AF; Filskov J; Sølund CS; Dietz J; Fourati S; Pawlotsky JM; Sarrazin C; Weis N; Schønning K; Krarup H; Bukh J; Gottwein JM
Hepatology; 2019 Sep; 70(3):771-787. PubMed ID: 30964552
[TBL] [Abstract][Full Text] [Related]
14. Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives.
Asselah T; Boyer N; Saadoun D; Martinot-Peignoux M; Marcellin P
Liver Int; 2016 Jan; 36 Suppl 1():47-57. PubMed ID: 26725897
[TBL] [Abstract][Full Text] [Related]
15. Exposure-Efficacy Analyses of Ombitasvir, Paritaprevir/Ritonavir with Dasabuvir ± Ribavirin in HCV Genotype 1-Infected Patients.
Khatri A; Mensing S; Podsadecki T; Awni W; Menon R; Dutta S
Clin Drug Investig; 2016 Aug; 36(8):625-35. PubMed ID: 27153823
[TBL] [Abstract][Full Text] [Related]
16. Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Mini-Tabs Plus Ribavirin for Children Aged 3-11 Years with Hepatitis C Genotype 1a.
Rosenthal P; Narkewicz MR; Yao BB; Jolley CD; Lobritto SJ; Wen J; Molleston JP; Hsu EK; Jonas MM; Zha J; Liu L; Leung DH
Adv Ther; 2020 Jul; 37(7):3299-3310. PubMed ID: 32451952
[TBL] [Abstract][Full Text] [Related]
17. Four weeks of paritaprevir/ritonavir/ombitasvir plus dasabuvir encountering dengue fever resulted in sustained virological response in an HCV patient: A case report.
Huang CF; Jang TY; Lu PL; Yu ML
Medicine (Baltimore); 2016 Nov; 95(47):e5304. PubMed ID: 27893666
[TBL] [Abstract][Full Text] [Related]
18. Treatment of HCV infection with direct-acting antiviral agents. Real life experiences from the Euro-Asian region.
Örmeci N; Gülşen MT; Sezgin O; Aghayeva S; Demir M; Köksal I; Güner R; Erarslan E; Asiller ÖÖ; Balkan A; Yaraş S; Çalışkan Kartal A
Turk J Gastroenterol; 2020 Feb; 31(2):148-155. PubMed ID: 32141824
[TBL] [Abstract][Full Text] [Related]
19. Paritaprevir/ritonavir/ombitasvir and dasabuvir for the treatment of chronic hepatitis C virus infection.
Cheng EY; Saab S; Holt CD; Busuttil RW
Expert Opin Pharmacother; 2015; 16(18):2835-48. PubMed ID: 26646975
[TBL] [Abstract][Full Text] [Related]
20. Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals.
Dietz J; Susser S; Vermehren J; Peiffer KH; Grammatikos G; Berger A; Ferenci P; Buti M; Müllhaupt B; Hunyady B; Hinrichsen H; Mauss S; Petersen J; Buggisch P; Felten G; Hüppe D; Knecht G; Lutz T; Schott E; Berg C; Spengler U; von Hahn T; Berg T; Zeuzem S; Sarrazin C;
Gastroenterology; 2018 Mar; 154(4):976-988.e4. PubMed ID: 29146520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
